NRG1、HER3在前列腺癌组织中的表达及其与临床病理特征和预后的关系  

The expression of NRG1 and HER3 in prostate cancer tissue and their relationship with clinical pathological features and prognosis

作　　者：王潇然[1] 陆巍[1] 于欣[2] 王永杰[2] 王勇[1] 廉吉虎[1] 李震霄[2] 宋海涛[2] Wang Xiaoran;Lu Wei;Yu Xin;Wang Yongjie;Wang Yong;Lian Jihu;Li Zhenxiao;Song Haitao(Department of Urology,Jilin Provincial People's Hospital,Jilin Province,Changchun 130021,China;不详)

机构地区：[1]吉林省人民医院泌尿外科,长春130021 [2]吉林省人民医院重症医学科,长春130021

出　　处：《疑难病杂志》2024年第1期63-67,共5页Chinese Journal of Difficult and Complicated Cases

基　　金：吉林省中医药科技项目(2020194)。

摘　　要：目的研究前列腺癌(PC)组织中神经调节蛋白1(NRG1)、人表皮生长因子受体3(HER3)表达与临床病理特征及预后的关系。方法选取2015年2月—2020年2月吉林省人民医院泌尿外科诊治PC患者96例,免疫组织化学检测组织中NRG1、HER3表达;Kaplan-Meier曲线(Log-Rank检验)比较不同NRG1、HER3表达对PC患者预后的影响;COX回归分析PC患者预后的影响因素。结果PC癌组织中NRG1、HER3阳性率分别为78.13%(75/96)、75.00%(72/96),高于癌旁组织6.25%(6/96)、8.33%(8/96)(χ^(2)/P=101.670/<0.001,87.771/<0.001)。TNM分期Ⅲ期、Gleason评分>7分及术前PSA水平≥20μg/L患者癌组织中NRG1、HER3阳性率大于TNM分期Ⅰ~Ⅱ期、Gleason评分≤7分及术前PSA水平<20μg/L(χ^(2)/P=6.181/0.013,8.533/0.003;7.731/0.005,6.769/0.009;6.508/0.011,7.376/0.007)。NRG1阳性组、HER3阳性组3年累积无进展生存率分别低于NRG1阴性组、HER3阴性组(χ^(2)/P=4.267/0.039,5.499/0.019)。TNM分期Ⅲ期、Gleason评分>7分、术前PSA≥20μg/L、NRG1阳性,HER3阳性是影响PC患者预后的独立危险因素[OR(95%CI)=1.448(1.118~1.875),1.401(1.138~1.724),1.353(1.059~1.728),1.338(1.057~1.692),1.293(1.014~1.649)]。结论PC癌组织中NRG1、HER3表达升高,与PC不良临床病理特征相关,是新的评估PC预后的肿瘤标志物。Objective To investigate the relationship between the expression of neuroregulatory protein 1(NRG1)and human epidermal growth factor receptor 3(HER3)in prostate cancer(PC)tissue and their clinical pathological characteristics and prognosis.Method Ninety-six PC patients diagnosed and treated in the urology department of Jilin Provincial People's Hospital from February 2015 to February 2020 were selected,and the expression of NRG1 and HER3 in the tissues was detected by immunohistochemistry;Kaplan Meier curve(Log Rank test)was used to compare the impact of different NRG1 and HER3 expressions on the prognosis of PC patients;COX regression analysis of prognostic factors in PC patients.Results The positive rates of NRG1 and HER3 in PC cancer tissues were 78.13%(75/96)and 75.00%(72/96),respectively,which were higher than those in adjacent tissues by 6.25%(6/96)and 8.33%(8/96)(χ^(2)/P=101.670/<0.001,87.771/<0.001).TNM stage III,Gleason score>7,and preoperative PSA level≥20μThe positive rates of NRG1 and HER3 in cancer tissues of g/L patients were higher than those in TNM staging stages I-II,Gleason score≤7,and preoperative PSA level<20μG/L(χ^(2)/P=6.181/0.013,8.533/0.003;7.731/0.005,6.769/0.009;6.508/0.011,7.376/0.007).The 3-year cumulative progression free survival rates of the NRG1 positive group and HER3 positive group were lower than those of the NRG1 negative group and HER3 negative group,respectively(χ^(2)/P=4.267/0.039,5.499/0.019).TNM stage III,Gleason score>7,preoperative PSA≥20μG/L,NRG1 positivity,and HER3 positivity are independent risk factors affecting the prognosis of PC patients[OR(95%CI)=1.448(1.118-1.875),1.401(1.138-1.724),1.353(1.059-1.728),1.338(1.057-1.692),1.293(1.014-1.649)].Conclusion The increased expression of NRG1 and HER3 in PC cancer tissue is associated with adverse clinical and pathological features of PC,and is a new tumor marker for evaluating the prognosis of PC.

关 键 词：前列腺癌 神经调节蛋白1 人表皮生长因子受体3 预后 

分 类 号：R737.25[医药卫生—肿瘤]